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Abstract 
Commercial and academic activities in the production of pharmaceuticals or other substances of 
industrial interests from genetically modified plants, i.e. molecular farming, have so far centred in 
the USA and Canada. Recent increases in EU activities and the proximity to market stage of the 
first plant-made pharmaceuticals, some of which from EU based companies, represent a call to ac-
tion for EU regulators. Drawing on the North American debate on molecular farming it will be ar-
gued that both the rationale of and the risk issues associated with molecular farming will differ 
significantly from those of first generation GM crops. Based on these differences, the suitability of 
the existing regulatory framework, which essentially was developed in response to the arrival of 
insecticide and herbicide tolerant crops for food and feed use, is discussed. Possible options for 
adapting the already complex EU regulatory system to cater for molecular farming are examined. 
It will be argued that the policy challenges posed will inevitably spark a broader public debate. As 
an issue for debate, molecular farming is located at two crossroads: of the risk debate on agricul-
tural biotechnology and the sustainability debate on renewables and greening of industry and of red 
and green biotechnology. Complex scientific, technical and legal issues, new issues at stake and a 
new pattern of actors are likely to give EU regulators a difficult time. 
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1 Introduction 
Since the mid 1990s an increasing number of research papers have described the production of 
substances of industrial interest from genetically modified (GM) plants, also referred to as “mo-
lecular farming”1. As a fundamental difference to present-day industrial crops most of these sub-
stances are not naturally occurring in these plants. The majority of R & D activities has so far focus-
sed on high-value proteins, especially on biopharmaceuticals (plant-made-pharmaceuticals or PMPs) 
(reviewed in Ma et al. 2005). Furthermore, plants are used for the production of enzymes and other 
substance such as fatty acids, bioplastics, spider silk, and gelatine (plant-made-industrials or PMIs) 
that can be used in various industrial sectors (e.g. Arcand and Arnison 2004, Hood et al. 2003, 
McKean 2003, Neumann et al. 2005, Scheller and Conrad 2005). 
Until recently, most R & D as well as public debates have centred in the USA and Canada, with 
little activity in the EU. As this article shows the picture in the EU is now changing and challenges 
for regulators are looming.  
This article is structured into the following sections: Firstly, the driving forces of the technology will 
be introduced. Secondly, the present status of commercialisation and the most important aspects of 
the North American public debate are reviewed. Thirdly, evidence will be presented that molecular 
farming is about to gain a foothold in Europe. In a forth section, it will be argued that specific haz-
ards and risk dimensions are associated with molecular farming. A fifth part identifies specific chal-
lenges for EU regulation by drawing on the technical and risk-related characteristics of molecular 
farming. In a concluding section, it will be argued that the policy development for molecular farm-
ing have to be pursued in a complex environment where unresolved problems with first generation 
GM crops2 are still prevalent. 
The focus of the article will thereby be on PMPs but frequent reference is given to PMIs.  
 
 
 
1 Some authors are using the terms biopharming interchangeably while (molecular pharming) is less inclu-
sive and refers to the production of pharmaceuticals only. 
2 First generation GM crops comprises so called output traits that are not aiming to directly benefit the final 
consumer. This group comprises various types of tolerance traits, mainly herbicide and insect tolerance. 
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2 Technology drivers 
Plant molecular farming is being developed as an alternative production system competing with a 
range of systems some of which are well established while others are under development. Table 1 
provides a comparison of plant molecular farming to other production systems. Bacterial produc-
tion systems have been used since 1977, with the landmark of recombinant insulin in 1982. Yeasts 
can be used for the production of more complex proteins and are for example used for the produc-
tion of Hepatitis B subunit vaccine. Mammalian cells have dominated the biopharmaceutical in-
dustry since the mid 1990ies because they can produce authentic complex proteins that are func-
tionally and in many cases structurally equivalent to their native counterparts. This is especially 
true for the three-dimensional structure – the folding of the protein and for the coupling of sugar 
residues to the protein – the glycosylation. Indeed more than half of all biological products – 
therapeutics, diagnostics, and vaccines – approved by the US Federal Drug Administration (FDA) 
are produced from mammalian cells.  
All three technologies of producing biopharmaceuticals – bacteria, yeast, and mammalian cells – 
require high-tech facilities and sterile production with mammalian cells being the most expensive 
one. They are well established production systems in contrast to animals and plants. Transgenic 
animals can produce biopharmaceuticals in their body fluids, providing a production system with-
out the need to kill the animals, for instance in the milk of mammals or in chicken eggs (animal 
pharming). This technology is presently being developed as an alternative option for production and 
is in a very similar stage of development and proximity to the market as molecular farming. Com-
mercial attention has so far focussed rabbits, cows, pigs, sheep, goats and chicken. Although pro-
ductivity in animal pharming is high, the process is time consuming and expensive. Furthermore, 
pharmaceutical proteins might affect the health and physiology of the production host thereby cre-
ating problems of animal welfare (Twyman et al. 2005). Production in chicken eggs seems to be 
more competitive in terms of timescales and production costs but is still in earlier stages of devel-
opment. 
Regulatory frameworks are established for both production and products from microbes and mam-
malian cell lines. A framework for animal pharming is still under development and has triggered a 
fierce ethical debate about animal welfare. Very recently, in mid 2006, the first biopharmaceutical 
from transgenic animals, a goat-derived drug for people with a rare inherited disease that leads to 
blood clotting, won approval of the European Medical Agency EMEA (Heuser 2006).  
Table 1: Comparison of production systems for recombinant human pharmaceutical proteins.  
System  
Overall 
cost 
Production 
timescale  
Scale-up 
capacity 
Product 
quality 
Glyco-
sylation  
Contamination  
risks 
Storage  
cost 
Bacteria  Low  Short  High  Low  None  Endotoxins  Moderate  
Yeast  Medium  Medium  High  Medium  Incorrect  Low risk  Moderate  
Mammalian  
cell culture 
High  Long  Very low  Very high  Correct  Viruses, prions and 
oncogenic DNA 
Expensive  
Transgenic 
animals 
High  Very long  Low  Very high  Correct  Viruses, prions and 
oncogenic DNA 
Expensive  
Plant cell  
cultures 
Medium  Medium  Medium  High  Minor  
differences 
Low risk  Moderate  
Transgenic 
plants 
Very low  Long  Very high  High  Minor  
differences 
Low risk  Inexpensive 
Source: Ma et al. (2003). 
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The main drivers of molecular farming seem to be of economic and technical nature (see Table 1): 
scaling-up of production by simply enlarging the cultivated area is considered an asset over pres-
ently used bioreactors that require expensive high-tech buildings, machinery and equipment and a 
time-consuming process for optimising production. This would enable producers to quickly adjust 
to changing market requirements (Raskin et al. 2002). Plant molecular farming would also provide 
sufficient capacity to manufacture biopharmaceuticals well beyond 10.000 kg/year – what consti-
tutes the highest annual tonnage presently derived from microbes or mammalian cell lines (see 
Figure 1). This is considered by industry as especially important for novel high-dose antibodies3 
that would be required in annual tonnages of 10.000 to 50.000 kg. For this kind of antibodies a 
shortage of production capacities is anticipated if relying on production in bioreactors only (Ko 
and Koprowski 2005). Beyond these high-volume biopharmaceuticals, most of presently used thera-
peutic proteins are sold at tonnages of less or even much less than 1.000 kg/year. Even in these 
cases it seems tempting to produce this amount on a total area of 2 to 40 hectares (see Table 2). 
 
Figure 1: Price and Sales of 89 therapeutic proteins presently marketed. 
Abbreviations: $/g…US$/amount of biopharmaceutical [g] 
Source: Steiner (2005). 
 
3 Monoclonal antibodies are widely used as diagnostic and research reagents. Their introduction into human 
therapy has been much slower. Still, more than 150 antibodies are presently in preclinical and clinical de-
velopment, many of them aiming at the treatment of cancer.  
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Plants are also an interesting alternative for proteins that are difficult or impossible to be produced 
in microbial systems. The protein resulting from the same gene might be slightly different in struc-
ture and function depending whether it is expressed in microbes, mammals or plants. Bacteria for 
instance, do not add certain sugar residues (glycosylation) and might not be able to correctly pro-
cess complex human proteins (Twyman et al. 2003). 
Product safety is another reason, frequently reiterated by industry as PMPs would be free of con-
taminating human or animal viruses, which is a concern in case of production from mammalian 
cell lines (Commandeur et al. 2003). While a presence of such viruses in mammalian cell lines 
might pose risks to human health, plant viruses are not known to infect humans. 
Potential savings in production costs were strongly emphasised until very recently (Seon et al. 2002) 
with industry in the meantime becoming less optimistic. In fact the production of biomass that in-
cludes the target protein is likely to be much cheaper compared to microbes and mammalian cells. 
According to earlier and optimistic estimates recombinant proteins could be produced in plants at 
2 to 10% of the cost of microbial fermentation systems and at 0,1% of the cost of mammalian cell 
cultures, although this depends on the product yield (Giddings 2001). Cut down in costs would, 
however, only affect the production of the crude protein, whereas the purification of the protein 
and formulation of the biopharmaceutical in the subsequent downstream processing amounts 50 to 
80% of the total production costs. Furthermore, higher compliance costs have to be anticipated for 
approval under respective GMO legislation and medicinal product legislation. The pre-clinical and 
clinical trials of new biopharmaceuticals are already a year-long and very expensive procedures re-
quired by pharmaceutical legislation. With PMPs companies are facing uncertainties and additional 
challenges how regulators, who are used to deal with contained production facilities and strictly 
controlled and validated production processes will deal with open-field production environments 
that will be influenced by weather, climate, soil and pests. 
Table 2: Estimate of productivity of different production platforms for pharmaceutical proteins.  
Production platform Productivity [kg/hectare/year] Area needed for 1.000 kg [hectare]
Maize (kernel) 0,2-4 800-40 
Rice/barley (seed) 2-12 80-12 
Alfalfa (foliage) 4-6 40-8 
Potato (foliage) 20-80 8-2 
Chicken egg 12 g/chicken 80.000 chickens 
Mammalian cell culture,  
15.000 l scale 
1,5 g/l;  
20 batches 
5 bioreactors 
Source: Baez (2004), modified. 
 
Finally, potential humanitarian benefits to developing countries are frequently mentioned by manu-
facturers and scientists, that is to say the availability and applicability of drugs might be improved 
(e.g. in case of oral vaccines, storage conditions in case of PMPs in kernels) (Ma et al. 2005). 
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3 North America:  
commercialisation being stalled 
Most commercial activity has so far centred in North America. More than 370 experimental field 
trials in the USA and in Canada with GM crops producing PMPs or PMIs4 are a good indicator for 
commercial interests. Another indicator are clinical trials: 16 PMPs were recently reported to be in 
various steps of clinical trials (Pharma-Planta 2005, Sauter and Hüsing 2006) with about 10 prod-
ucts – including veterinary drugs – getting closer to market stage (see Table 3)5. Very recently, a 
poultry vaccine from plant cell culture was the first PMP that achieved regulatory approval.6 Horn 
et al. (2004) anticipates market approval for 12 products from plants including vaccines, antibod-
ies, and enzymes by 2009. Some enzymes and other substances are already produced on a small 
scale through molecular farming for commercial use as fine chemicals (Spök and Klade 2005).  
Table 3: Plant-made pharmaceuticals approaching market stage.a) 
Product Application Plant host(s) Statusb) Company 
Biopharmaceuticals for humans 
CaroRxTM  AB carries prophylaxis  Tobacco II Planet Biotechnology, 
USA 
Gastric lipase Therapeutic enzyme Maize II Meristem Therapeutics, 
France 
Human intrinsic factor Dietary Arabidopsis II Cobento Biotech AS, 
Denmark 
AB AB cancer vaccine Tobacco II Large Scale Biology 
Company, USA 
Hepatitis antigen Oral vaccine against 
Hepatitis B 
Potato II Arizona State University 
Biopharmaceuticals for animals 
 Vaccine against feline 
parvovirus 
Tobacco Advanced Large Scale Biology 
Company, USA 
Human lactoferrin Anti-infection,  
anti-inflammatory and 
iron-binding properties 
Rice Advancedc Ventria, USA 
Human lysozyme Anti-infection,  
anti-inflammatory and 
iron-binding properties 
Rice Advancedc Ventria, USA 
HN protein of  
Newcastle Disease Virus  
Poultry vaccine Plant cell culture Advanced Dow Agro Sciences, USA
a) This table only includes PMPs which are in the advanced stages in terms of clinical testing;  
b) For human biopharmaceuticals: phase of clinical trials;  
c) Already commercially available as fine chemicals. 
Source: company websites. 
 
4 www.isb.vt.edu/cfdocs/fieldtests1.cfm;  
www.inspection.gc.ca/english/plaveg/bio/mf/sumpnte.shtml. 
5 This also includes two products from EU based companies, Meristem Therapeutics and Cobento, the for-
mer of which is partly conducting field trials in the USA. 
6 www.dowagro.com/newsroom/corporatenews/2006/20060131b.htm. 
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Consequently, the North American biotech industry is now keen to obtain a green light for com-
mercial production, which would include open field production in food crops. Therefore, they are 
eager to establish a regulatory framework that would allow for commercialisation. The United States 
Department of Agriculture (USDA) and the Canadian Food Inspection Agency (CFIA) have become 
active quite early in the process. Support for this technology has come from certain growers’ or-
ganisations, e.g. National Corn Growers Association (2001) and patients’ alliances, e.g. IAPO 
(2005)7. Confronted with strong pressure from the food industry, environmentalists and consumer 
organisations regulators are however proceeding slowly and with care (Cassidy and Powell 2002, 
Ellstrand 2003, Jones 2003, Miller 2003, Kamenetsky 2003, UCS 2003). 
Given the US preference for maize as a production platform, the key policy issue obviously is the 
risk of contamination, i.e. if pharm maize would end up in the food or feed chain (California Coun-
cil on Science and Technology 2003, Felsot 2002, Pew 2002). Environmentalists and consumer or-
ganisations are highlighting health and environmental risks and the food industry is – on top of 
that – also concerned about the impacts of perception – recalling the consequences and costs of re-
cent cases of accidental contamination (see further below). These concerns had been amplified by 
initiatives to grow pharm maize in the corn-belt region.  
Canadian authorities are embarking on a more precautionary way. Unlike in the USA, they are ex-
plicitly recommending the use of non-food crops for PMPs and are limiting the size of experimen-
tal field trials to one hectare per province and year (CFIA 2003). 
The sensitivity of certain actors results from contamination incidents, especially the case of StarLink 
(EPA 2000, Ellstrand 2003, Freese 2002, Spök, et al. 2003) and ProdiGene (Cassidy and Powell 
2002, Choi 2002a, 2002b, Jones 2003):  
StarLink is a GM maize variant harbouring the bacterial protein Cry9C. This protein is specifically 
toxic to a variety of pests and thereby renders the maize insect resistant. In 1998 the US Environ-
mental Protection Agency (EPA) did not exclude the possibility of an allergic potential and granted 
a tolerance exemption for feed and industrial use only (i.e. not human food). The EPA required a 
buffer zone of 200 m between the GM and any conventional maize to avoid pollen contamination. 
StarLink maize and maize derived from the buffer zone were to be processed separately from food 
maize. Despite such safety measures Cry9C was detected in Taco Chips in September 2000 and 
subsequently also in maize flour. USDA eventually detected Cry9C in 9 to 22% of all maize sam-
ples. Given the huge variety of processed maize products millions of people are assumed to have 
consumed contaminated maize products before those products were recalled and removed from su-
permarket shelves. Despite a considerable number of consumer reports about allegedly allergic 
symptoms, in no case could actual allergic symptoms be attributed to the GM maize. Nevertheless, 
call-backs and compensations were reported to amount to billions of US $. 
It was later revealed that contaminations occur via commingling after harvest. Commingling might 
happen for instance, if storage facilities, equipment and machinery are used for both GM and con-
ventional maize varieties without properly cleaning them in between. Farmers or wholesalers han-
dling such material might also be not aware to keep these types of maize separate. In fact, it turned 
out that some of the farmers and farm workers had not received appropriate information and train-
ing on both sowing and trading restrictions. In addition, there were indications of pollen flow to 
conventional maize varieties. 
While the StarLink case was about maize grown for feed use on large acreages the ProdiGene in-
cident was about pharm maize grown on small areas. In 2002 USDA’s Animal and Plant Inspec-
tion Service (APHIS) staff recorded two cases of violations against conditions for deliberate re-
 
7 www.ncga.com/news/CC/volume10/ccVol10n03.html. 
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lease of GM pharm crops. In both cases GM maize volunteers resulting from field trials of the US 
molecular farming company ProdiGene were detected in conventional soybean fields.  
In the Iowa case, volunteers8 were detected in a late stage of development. Given the possibility of 
pollen flow to surrounding maize fields, more than 60 hectares of maize had to be incinerated. 
In Nebraska, ProdiGene did not remove the volunteers despite the order to do so was issued by in-
spectors of the USDA-APHIS. Thus, the volunteer pharm maize was harvested together with the 
soybean plants. About 14.000 tons of soybeans were put in quarantine by APHIS. ProdiGene re-
portedly bought the entire batch of soybean. The US Food and Drug Administration (FDA) stated 
only minimal risks if at all. Nevertheless, economic damages in this case were considerable: fines 
and financial damage were reported to have amounted to some 3 million US $ and eventually led to 
the bankruptcy of ProdiGene. In this case total economic damage was small compared to StarLink 
but, according to several commentators, the incident nevertheless caused a severe setback for the 
molecular farming industry. 
 
 
 
4 European Union: late on the scene 
In the EU commercial R & D activities in molecular farming have been increasing over the last five 
years: at present, at least 24 companies are active in this field, most of them specialised into this 
technology (see Table 4). Recently, with Syngenta, Bayer and BASF, EU-based multinational com-
panies moved into the arena. Cobento and Meristem Therapeutics might be among the first to mar-
ket a biopharmaceutical for use in humans from plants (see Table 3). Meristem is producing its gas-
tric lipase in open field production using maize (presently on 20 hectares in France) and anticipates 
full scale production on 1.000 hectares following market authorisation in 2009 (Burtin 2006). The 
gene for the enzyme lipase was derived from dog and the product is intended to be used for treat-
ing Cystic Fibrosis. 
Pharma-Planta, a research consortium under the European Commission’s 6th Framework Programme 
is pioneering academic research activities in partnership with a small number of European firms9. 
The European Technology Platform “Plants for the Future”10 which is advising the European Com-
mission on research topics for the upcoming 7th Framework Programme, set a particular focus on 
industrial crops, including molecular farming (Plants for the Future 2004, 2005). These activities 
have very recently brought molecular farming onto the radar of EU regulators and risk assessors. 
 
  8 A crop which sprouts unexpectedly in a surprise location. Birds and animals often plant them in their drop-
pings, or the seeds are carried by wind or humans to new locations. In the case of maize, kernel might re-
main in the soil, survive the winter and sprout in the next growing season. If the field is being used for 
some other cultivars, the maize might be a weed. 
  9 www.pharma-planta.org. 
10 EU Technology Platforms are led by industry and serve as frameworks for stakeholders, to define research 
and development priorities, timeframes and action plans on a number of strategically important issues 
where achieving Europe’s future growth, competitiveness and sustainability objectives is dependent upon 
major research and technological advances in the medium to long term. The European Technology Plat-
form „Plants for the Future” is coordinated by European Plant Science Organisations and EuropaBio and 
is advising the European Commission on biotechnology and plant genomics. 
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Table 4: European companies and organisations active in molecular farming.a) 
Company/Organisation  Plant host(s) Products/Indications 
Agrenvec, Spain Brassica (viral expression) Contract manufacturing 
BASF, Germany Brassica, tobacco Poly unsaturated fatty acids 
Bayer Crop Science, 
BioScience, Germany 
n.sp. Antibodies etc. 
Cobento Biotech, Denmark Arabidopsis Human intrinsic factor transcobalamin protein 
CropDesign, Belgiumb) Maize, rice Contract manufacturing 
ERA Plantech, Spain Protein bodies in most plant 
tissues and species 
Product-neutral productivity improvements 
Fraunhofer IME, Germany Tobacco, corn, rice, wheat, 
tomato, plant suspension cells 
Antibodies, vaccines (injectables and oral administration),
enzymes for oncology and infectious disease 
greenovation Biotech 
GmbH, Germanyg) 
Moss Monoclonal antibodies and other complex proteins 
Icon Genetics AG, 
Germanyd) 
Tobacco, Nicotiana benthamiana, 
spinach, red beets 
Interferon, somatotropin, restriction enzyme, single-
chain antibodies, monoclonal antibodies, antigens, 
glucocerebrosidase, thaumatin, albumin, DNAse, 
RNAse inhibitor, insulin 
LemnaGene S.A., Francef) Lemna spp. n.sp. 
Maltagen Forschung GmbH, 
Germany 
Barley, malt Lactoferrin, lysozyme, human serum albumin, 
hepatitis vaccine, edible vaccines 
Meristem Therapeutics, 
France 
Maize, tobacco Gastric lipase (MERISPASE®); albumin; human collagen; 
human lactoferrin; human IgA (x4); dust mite allergens; 
murine IgM (monomeric); human plasma proteins 
Novoplant GmbH, Germany Tubers, rape seed, flax seed, peas Orally administered antibodies for animal health 
ORF Genetics, Icelande) Barley, lettuce Growth factors, proteases, antibodies, vaccines 
Phyton Biotech, Germany Plant cells Amongst others: growth hormone receptor 
antagonist for treating acromegaly, cancer, diabetes 
Pharma-Planta Project 
European Community 
Maize, tobacco (various plants) Antibodies, vaccines, others 
PlantBio Products, Spain Chloroplast transformation Bioplastics 
Plantechno SRL, Italy Rice, wheat, tomato, maize, 
poplar, Agaricus, barley 
Enzymes 
Planton, Germany Potato Contract manufacturing 
Plant Research International, 
The Netherlands 
Platform technologies applicable 
in all plant hosts (tobacco, 
potato, tomato, rice, others) 
Antibodies as a model: vaccines for oral application 
and targeted delivery 
SunGene, Germanyc) Rapeseed, potato, tagetes, 
Arabidopsis, tobacco and tomato 
Secondary metabolites e.g. carotenoids and vitamins 
for food, feed and health 
Syngenta, Switzerland Safflower etc. Biopharmaceuticals for a range of indications, including 
antibodies, enzymes and other protein therapeutics 
UniCrop Ltd, Finland Camelina sprouts Model proteins: monoclonal antibodies, immunoglobulin
fusion protein; human serum albumin, enzymes 
a) Sources: Ma et al. (2005), Sauter and Hüsing (2006) modified and updated;  
b) Acquired by BASF in 2006;  
c) Joint venture of BASF Plant Science, the Institute of Plant Genetics and Crop Plant Research;  
d) Recently acquired by Bayer;  
e) Iceland is not a member of the EU but belongs to the European Economic Area;  
f) Recently acquired by the US company Biolex Therapeutics;  
g) Licence agreement with Bayer. 
Abbreviations: n.sp.: not specified. 
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5 Pharm crop risk issues differ 
In principle most of the potential risks discussed for first generation GM crops11 would apply to 
molecular farming as well. Nevertheless, three reasons are suggested here as to why risks associ-
ated with molecular farming could have different characteristics: 
Firstly, unlike first generation GM crops, PMPs are designed to have a biological effect on man 
and/or higher animals, hence the hazard characteristics of the introduced protein might be of con-
cern. 
Secondly, an entirely different breeding rationale applies. Plants will be optimised e.g. for maximum 
yield, special morphology and growth habit suited to a specific harvesting method that can be used 
with the PMP application, absence of metabolites that may compromise product integrity or qual-
ity during bioprocessing (Davies 2005). Pharm crops are considered production facilities that have 
to be optimised for maximum yield of the target substance. Human and environmental exposure 
could therefore be increased compared to first generation GM crops. Depending on the expression 
system maximum yields of up to 25 and 31 % of total soluble protein (TSP) (Daniell et al. 2005, 
Fischer et al. 2004) and 80% TSP (Gleba et al. 2004), Marillonnet et al. 2004) have been achieved 
(the latter of which in greenhouse experiments). This would constitute a 700 to 5.000 fold increase 
in transgene products compared to first generation GM crops (Spök 2006).12 
Thirdly, the likelihood of unintended secondary effects might be higher, and the hazard character-
istics of GM plants might thus be of concern. Unintended secondary effects are already a big issue 
with single gene insertions of first generation GM crops, but the number and significance of genomic 
changes in the forthcoming generation of crops increase the likelihood of unintended effects and 
the associated uncertainties, all of which will need to be addressed in regulation. This is because 
these plants are likely to include several genetic modifications at the same time. Resistance genes 
might be introduced to avoid problems with pests, pathogens, and weeds which would otherwise 
require applying pesticides and herbicides. These substances might cause concerns as drug con-
taminants. Moreover, genetic modification for easy and unambiguous visual identification of seeds 
and plants are suggested which would enable a simple differentiation of plants, seeds or fruits not 
intended for consumption (Commandeur et al. 2003, Ellstrand 2003). In addition, molecular con-
finement technologies are being introduced involving several complex changes in the plant ge-
nome. Molecular confinement aims at avoiding gene dispersal via pollen or rendering plants infer-
tile (Daniell 2002).  
Whether this would translate into higher health and environmental risks would, however, depend 
on the particular case and also on the category. With many PMIs there might be no intention of a 
biological effect in humans or animals. Nevertheless, hazardous properties could also be associated 
with this category. Avidin, for instance, which is presently produced as a fine chemical, is toxic to 
many insects and might cause Vitamin H deficiency in higher animals and humans. Aprotinin, to 
take another plant derived fine chemical, is considered a reproductive hazard. In contrast, enzymes 
like lipases or trpysin might pose less health risks in case of food contamination, because both 
types of enzymes are ubiquitous in nature (Freese 2002). Moreover, trpysin is considered safe and 
used in food production in the USA and elsewhere. Health risks might not necessarily be restricted 
 
11 Mostly herbicide tolerant and insect resistant crops. 
12 The yield of 80% of TSP was achieved using a production system that is not intended for open field culti-
vation. It nevertheless shows what is technically feasible at present. For open field cultivation, yields of 10 
to 35% might be more realistic – but might also be optimised as technology improves. 
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to toxic or allergenic effects, though. For instance, a human hormone could have detrimental ef-
fects if contaminating the food chain. A vaccine, e.g. a virus protein, might lead to desensitization. 
If so, those affected would perhaps not develop a desired immune response when vaccinated (Kirk 
et al. 2005). Consequently, the hazards might very much depend on the particular case. 
Exposure, another key issue in risk assessment, will not only depend on the amount of protein pro-
duced but also on the area of land used for cultivation. Commercial production of large amounts of 
PMPs could take place on 10 to 1.000 hectares (see Table 2), which is in the range of larger US 
field trials with first generation GM crops. Beyond possible contamination accidents exposure is, 
therefore, more likely restricted to workers processing or handling the crops. Environmental expo-
sure will also be different due to the higher concentration of proteins/unit area. Environmental ex-
posure and spread could, however, be diminished by molecular, physical and organisational con-
finement measures while worker’s exposure could be reduced by protective measures. Unintended 
secondary effects (see further below) might be of less concern in the case of small cultivation ar-
eas, especially if confinement measures are effective. 
Regulatory and industry experts are thus framing the issue as a confinement problem. US and Ca-
nadian regulators have been working together with industry on a variety of physical and organisa-
tional confinement measures that can be applied to avoid outcrossing, spillage of seeds or biomass, 
and commingling with food or feed crops (see Table 5) and researchers are working on molecular 
confinement mechanisms that aim at avoiding gene dispersal by a variety of mechanisms (Daniell 
2002). Most of the molecular confinement mechanisms being proposed (USDA 2003), however, are 
‘leaky’, i.e. not working 100%, and still far from being used for commercial production (Ellstrand 
2003). Organisational and physical confinement measures can fail due to human error. It has there-
fore been proposed that a combination of several different confinement measures have to be applied 
at the same time to establish a redundant system which would provide a sufficient level of safety.  
What is considered by the biotech industry and regulatory experts as sufficient risk mitigation meas-
ures might, however, not be sufficient for the food industry or consumer and environmental groups, 
and perhaps also for the general public. Beyond and independent of any health or environmental 
harm, considerable economic damage might occur in case of contamination of the food and feed 
chain. Given the lessons of the StarLink and ProdiGene incidents, serious economic consequences 
might result from accidental commingling even in case there are no or very little health or environ-
mental risks. Anxieties of civil society and the food and feed sector might also be sparked by dis-
cussions to use the remainders of biomass after the pharmaceutical component has been separated, 
e.g. for feed purposes instead of expensive incineration, also referred to as “dual-use” (Freese 2002). 
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Table 5: Physical and procedural confinement measures proposed. 
• Distinct visual markers 
• Time shift in planting compared to food/feed crops nearby  
• Cultivation in remote areas 
• Fencing, restrictions to enter 
• Extended isolation distances (e.g. 1600/800 m for normal pollinating maize), fallow zones, temporal 
shifts in planting (e.g. 21 days for maize), other plants as pollen barriers, detasseling (maize), covering 
of inflorescence 
• Dedicated equipment, machinery and processing facilities 
• Preliminary on-farm processing 
• Post-release monitoring 
• Procedures for 
? seeding, transplanting, side-maintenance, harvesting, seed cleaning  
? storage, drying and processing of biomass  
? disposal of biomass e.g. autoclaving, incineration etc. 
? handling and cleaning of machinery, equipment and containers  
? monitoring during growing seasons and post-harvest land use  
? dealing with non-compliance with terms and conditions for confinement  
• Records and reporting of all activities dealing with the cultivation and transport to processing facility, 
documentation and logs for seeds and biomass  
• Training of staff and workers to adequately handle the plant material  
• Emergency response/contingency plans 
• Strict control of compliance to measures imposed – either by regulators or by other independent 
institutions (third-party audits) 
• Test for GMO detection in raw agricultural commodity 
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6 EU regulators  
might need to role up their sleeves 
Pharm crops will be operated similar to pharmaceutical production facilities and will be further im-
proved accordingly. Risk characteristics are likely to differ from first generation GM crops and risk 
mitigation requirements will become a focal issue. These characteristics are likely to pose a number 
of challenges to policy makers and regulators in the EU (drawing on Spök and Klade 2005): 
Obviously, there will be a need to review and update current risk assessment approaches and guide-
lines established for first generation GM crops. Possible challenges for risk assessors include the 
applicability of the concepts of substantial equivalence and familiarity which both play key roles in 
the risk assessment of presently marketed GM crops. Familiarity refers to experiences gathered with 
the host crop in conventional agriculture (Barret and Abergel 2000). This concept might however 
be less applicable if non-food/non-feed plants with which there is less experience are used, for in-
stance safflower in Canada. Likewise, the concept of substantial equivalence might be considered 
less instructive. A GM crop that is considered substantially equivalent to a conventionally bred crop 
is deemed to be as safe as the conventional crop. If the conventional comparator has a history of 
safe use or consumption this establishes a relative safety that is considered acceptable. Substantial 
equivalence is normally being established by drawing on a comparative analysis encompassing a 
range of plant ingredients as well as morphological and agronomic parameters. Identified differences 
should then guide the risk assessment. If pharm crops, as explained above, had been subjected to 
multiple and perhaps more substantial changes of the genotype it might be either difficult or less 
significant to establish an equivalence status by just drawing on the presently used small range of 
analytes and characteristics. Moreover, if opting for non-food/non-feed crops one would most likely 
end up with a crop where there is less knowledge and experience in agricultural and environmental 
terms compared to presently used staple crops and where there is no long-established safety for con-
sumption and use.  
Furthermore, especially with PMPs another step might be added to risk assessment: to thoroughly 
assess and to advise on the appropriate level of confinement measures which could include all kind 
of molecular confinement measures but also the physical and organisational measures listed in 
Table 5.  
Second, the perhaps most important goal of regulation might be the avoidance of any cross con-
tamination of the food and feed chain as well as the question of “coexistence” between these kind 
of industrial crops and food and feed crops. In case of using food crops for open field production 
of PMPs and perhaps also PMIs there might be a need for mandatory and harmonised coexistence 
rules at the EU level supplementing or replacing the present EU guidelines. These rules might 
need to include threshold limits in case of accidental contamination and for liability reasons. The 
present EU harmonised threshold limits of 0,9% and 0,5% for GM crops in conventional food 
might not be considered acceptable from both a health and a public perception point of view. Con-
versely, it is difficult to envisage a zero tolerance policy, as it is presently pursued for molecular 
farming by the USDA (USDA 2006, Howard and Donnelly 2004). Even thorough on-site risk 
mitigation measures and extended safety distances of up to 1,6 km for maize producing PMPs 
(USDA 2006) are not considered to be a hundred percent effective by many commentators. Simi-
lar concerns are voiced by Canadian regulators (CFIA 2005). According to some commentators 
zero tolerance would not even be feasible if only non-food/non-feed crops would be used. Given 
the huge differences that can be assumed for the hazardous properties of the various kinds of 
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PMPs that can be envisaged, substance-specific threshold limits would be more likely. In analogy 
to the limit values for pesticide residues13 limit values will need to be harmonised across the EU, 
either for specific substances or for particular categories of PMPs, as differences in limits between 
Member States would hamper food and feed trade. Furthermore, this would not only be an issue of 
contaminating conventional or organic crops – it would also pertain to GM food/feed crops. Such a 
scenario would render food control a more complex business.  
A related issue would be the question of liability which is of course of paramount interest for the 
food and feed industry as well as for farmers (Smyth et al. 2002). As shown for the StarLink and 
ProdiGene incidents liability issues are not just academic speculation. Whether and under what 
particular conditions biotech companies, farmers or food producers could be held liable for any 
health, environmental and economic damage that might occur is an especially significant question. 
In comparison to first generation GM farming this would also be an issue for farmers and food 
producers using GM crops.  
Given these constraints molecular farming companies and even regulators might opt for an addi-
tional authorisation under EU Regulation 1829/200314 for use as food and feed. Such a permit 
would relax the contamination threshold, ease potential liability cases and open the possibility to 
use remainders of production as feed. On the other hand, given the safety requirements embedded 
in this legislation and the difficulties of the EU level procedures for market authorisation of GM 
crops and food this is not likely to be an easy ride and might only be feasible for certain PMIs 
rather than for PMPs. 
The need for keeping food/feed and pharm crops separate would, however, not be a concern of food 
and feed producers only. With PMPs it might well work the other way round as manufacturers can 
be expected to avoid contamination of their drugs, e.g. with food and feed crops, pests and pesti-
cides to maintain the purity and safety standards important for a validated drug production process. 
In certain areas concerns might, however, differ between food and drug producers. For instance, 
outcrossing of normal food or feed maize into pharm maize, might be a particular concern for seed 
producers of pharm crops. Pharm maize seed production might therefore require safety distances 
and other measures to maintain the purity of the seeds. At commercial production stage the same 
contamination of pharm crops might be of less concern – especially if the PMP will be purified from 
the green plant material. Furthermore, for PMI producers aiming at bulk products there might be 
fewer incentives for confinement. Consequently, confinement triggered by these self-interests might 
provide additional but still limited reassurance to food and feed producers. 
Therefore, it has to be questioned whether the presently established coexistence framework for GM 
and non-GM agriculture in the EU, based on non-mandatory EU recommendations and Member 
State legislation might be considered sufficient to deal with this kind of industrial crops. Even be-
fore the first PMP will be commercially cultivated in the EU: if this technology takes off in the 
USA, Canada or any other country exporting food or feed to the EU, EU regulators and food con-
trol might have to deal with questions of threshold limits earlier than expected.  
Repeated reports of GM crop contamination of EU imports have kept regulators and consumers and 
environmental NGOs alert and are less likely to maintain or regain consumer trust in presently used 
segregation systems: e.g. in case of maize Bt10 (Macilwain 2005) and most recently contaminations 
 
13 Regulation (EC) 396/2005 of the European Parliament and of the Council of 23 February 2005 on maxi-
mum residue levels of pesticides in or on food and feed of plant and animal origin and amending Council 
Directive 91/414/EEC. 
14 Regulation (EC) 1829/2003 of the European Parliament and of the Council of 22 September 2003 on ge-
netically modified food and feed foresees a mandatory authorisation procedure prior to marketing any food 
or feed from GMOS in the EU. 
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by GM rice lines one of which originates not from commercial production but from US field trials 
(Pew 2006) while the other might come from illegal cultivation in China (Marris 2006). In these 
cases a zero contamination policy applies in the EU as these GM lines are not authorised for com-
mercial production. The potential higher risks of commingling and contamination in developing or 
less industrialised countries might be a particularly neglected issue as producers are increasingly 
conducting their field trials in countries such as Chile, Cuba, India, South Africa (because this makes 
it possible to get more than one harvest per year and ironically because of the more difficult regu-
latory environment and the less favourable public perception in the EU). 
Furthermore, there is no equivalent procedure in the EU to what is envisaged in the US as a com-
mercialisation track for molecular farming. The EU Directive 2001/18/EC15 foresees two different 
authorisation tracks: time- and area-limited field trials (Part B) and placing on the market of GM 
crops including import, transport, processing, handling, storage and cultivation (Part C). Part B pro-
cedures are national and authorisation can be granted by the respective Member State only, though 
derived products must not be used for commercial purposes. Part C foresees a centralised procedure 
involving all Member States in both risk assessment and decision making and authorisations would 
allow for commercialisation in all EU Member States. Both procedures might not be entirely ap-
propriate for PMPs.  
Many PMPs and perhaps also PMIs (e.g. fine chemicals for research and diagnostics) are intended 
to be produced on a small scale only and could be produced on areas that compare to large scale 
field trials of GM crops. Thus, it can easily be envisaged to cultivate, transport and process these 
plants within one Member State. Cultivation or processing of such plants might be conducted in-
house or by contractors under supervision of the manufacturer. Such seeds and plants are unlikely 
to be traded on the market.  
Given the US experience companies might in fact be keen to stay under strict regulatory oversight 
during the commercial production stage.16 Thus, companies might in fact be happy with Part B type 
authorisations. However, according to EU law this would only work until the commercialisation 
step has been reached. 
Part C authorisation procedures would allow for commercialisation and would be more proportion-
ate for the increased rigour of their risk assessment and the mandatory monitoring. In the complex 
EU policy environment, though, there might be continued unpredictability around eventual authori-
sation decisions.  
National Part B procedures would thus be more straightforward but would not be considered suffi-
cient in terms of risk assessment and monitoring and perhaps not as acceptable, if there is any chance 
that possible contamination might effect commercial food and feed products intended for other EU 
countries.  
Therefore, a separate authorisation track might be envisaged for PMPs and certain types of PMIs. 
Given the sensitivity of the issue it is however difficult to envisage such a procedure becoming es-
tablished at any national level without the involvement of the EU or other National Authorities. 
One would perhaps not need such a separate track in case of PMIs and if no health or environmental 
concern could be identified (and an authorisation as food and feed becomes feasible) as well as in 
 
15 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate 
release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC 
establishes a mandatory authorisation procedure for import, handling, processing and cultivation of GM 
crops. 
16 www.bio.org/healthcare/pmp/factsheet4.asp. 
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case of production of PMPs under containment17. Table 6 highlights how the different characteris-
tics of PMPs would translate into different requirements for authorisation. 
Table 6: Anticipated market authorisation requirements  
for GM plants used in the production of pharmaceuticals 
GM food and feed crops Molecular farminge) GM food and feed crops  
Field trial stage – Part Bf)  Commercial stage – Part Cg) 
Scale/area Normally in the range of  
0,5 to 20 hectares 
In rare cases: beyond  
100 hectares 
PMPs: a few to more 
than 1000 hectares 
Unlimited 
Authorisation  One Member State only Not absolutely required 
in more than one  
Member State 
Entire EU 
Derived products can be used 
for commercial purposes 
NR R R 
Trading of seeds and  
propagating material 
NR NR R 
Import Rb) R/NRc) R 
Transboundary transport Rb) R/NRc) R 
Processing, Handling Rb) R/NRc) R 
Cultivation in more than  
one Member State 
Rb) R/NRc) R 
Supervision of on-site  
requirements 
Rd) Confinement and  
containment measures 
might need strict  
supervision 
n.a. 
Monitoring  Not mandatory More extended  
monitoring requirements
might be needed 
Mandatorya) 
Risk assessment National Competent Authority; 
requirements might differ  
between Member States 
Could be both EFSA and National  
Competent Authorities;  
requirements are  
harmonised at EU level 
Regulatory oversight National Competent Authority To be established European Commission 
Decision making procedure Member State level To be established EU level 
a) General surveillance applies, requirements for case-specific monitoring requirements have to be decided 
for each application;  
b) Only for non-commercial purposes;  
c) Depending on the particular case. Not necessarily required as transport, processing, handling and 
cultivation could be conducted in one Member State only;  
d) Supervision might differ between Member States;  
e) Anticipated requirements for molecular farming;  
f) Requirements and responsibilities in case of field trials with GM crops (Directive 2001/18/EC, Part B);  
g) Requirements and responsibilities in case of placing on the market of GM crops (Directive 2001/18/EC, Part C).  
Abbreviations: R/ NR: required/not required; n.a. not applicable. 
Source: Compiled on the basis of Spök and Klade (2005). 
 
17 Containment or contained production in this article refers to physically closed buildings and appropriate 
measures to avoid any release of the GMO or viable parts of it to the environment. Contained use of GMOs 
is regulated in the European Union under Council Directive 90/219/EEC of 23 April 1990 on the contained 
use of genetically modified micro-organisms. 
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A separate track for molecular farming that would for instance restrict cultivation to one country or 
even to a particular region in one country might also help to tackle an inherent European problem 
– the diversity of European agricultural environments, of agricultural structure and practice. Both 
aspects are constantly creating problems with the centralised EU procedure of environmental risk 
assessment and monitoring requirements and contributed to extended timelines in market authori-
sations. If cultivation would be restricted to a particular region, environmental risks assessment and 
measures to be taken could be tailored to the specifics of this regional environment.  
Finally, most of what is said above pertains to open field cultivation; however, there are alternative 
production approaches using contained facilities, using e.g. plant cell culture, duckweed, moss or 
root exudation (see Box 1). Contained production would drastically reduce the risks of food and 
feed contamination while lacking some of the advantages of open field production. Furthermore, 
whereas confinement measures for open field production of PMPs are likely to be discussed and 
agreed at the EU level, commercial production under contained conditions is still under regulatory 
oversight of the particular Member State according to EU Directive 90/219/EEC.18 Greenhouse 
production would also be an alternative option, for they are normally considered as contained fa-
cilities. Greenhouse space for contract cultivation is presently available up to some 30 hectares19 
which would be sufficient for producing significant quantities of several high-value proteins.  
Box 1: Contained production approaches in plant molecular farming 
Plant cell culture 
Plant cell lines, mainly from tobacco cultivars are grown in a very similar way as mammalian cell lines. 
In the last 15 years production of more than 20 different recombinant proteins have been demonstrated 
including antibodies, hormones, growth factors and cytokines. Purification of the target protein might 
be simpler compared to agricultural-scale production (Doran 2000, Hellwig et al. 2004). The first com-
mercially approved PMP, a poultry vaccine is being produced from plant cell culture (see fn 6). 
Root exudation 
The formation of hairy roots can be induced by genetic modification and enable root tissue to be cultured 
in liquid medium. A variety of plant metabolites have been produced from hairy roots and excreted 
into the liquid medium which makes purification easier. Proteins produced so far include antibodies, 
phosphatase, ricin B fusion protein (Fitzgerald 2003, Gleba 1999, Guillon et al. 2006). 
Moss 
A particular moss variety which is very susceptible to transformation with recombinant DNA is cul-
tured in bioreactors. Proteins can not only be secreted into the medium but also – via additional ge-
netic modification – being modified to change from plant to human glycosylation pattern (Decker et al. 
2003, Schaaf et al. 2005). 
Lemna 
Lemna or duckweed are small plants growing on the surface of ponds, lakes and rivers. The plant has 
been genetically modified to produce twelve monoclonal antibodies including small peptides and large 
multimeric enzymes (Fitzgerald 2003, Gasdaska et al. 2003). 
 
 
 
18 See fn 17. 
19 E.g. http://www.bevoagro.com/index.html. 
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Some PMPs, however, (e.g. allergens for diagnostics or medical therapy, vaccines, or hormones) 
might call for higher levels of containment than others. Member States might have different opinions 
about what would constitute an appropriate level of containment for a particular substance. There 
might even be different ideas about the borderline between contained production and deliberate re-
lease. For instance, a commercial production using net-houses, as is envisaged with potatoes in Den-
mark (Berglund 2006) might be considered by one Member State a rather unproblematic authorisa-
tion under the contained use Directive 90/219/EEC, whereas others might classify the same practice 
as deliberate release that would require an application under Directive 2001/18/EC obtained after 
going through a much more cumbersome EU procedure (Ball, Haas, personal communication). Such 
differences will need to be reviewed and perhaps harmonised by EU regulators. 
 
 
 
7 Towards an open debate  
– facing complexity at various levels 
Previous sections have illustrated the different characteristics of molecular farming and its associ-
ated health and environmental risks compared to first generation GM crops. Increased activities in 
European R & D and the proximity to market stage of first products of plant molecular farming are 
now drawing the attention of EU regulators to this issue. As analysed above, several challenges are 
posed to regulators in order to allow for commercialisation of molecular farming in the EU includ-
ing, e.g. avoidance of contamination of the food and feed chain, set up of coexistence measures in-
cluding threshold limits, establishment of an authorisation track that is appropriate for commercial 
open field production, and to better define what would constitute a contained production. Risk asses-
sors are also called on to reconsider their assessment concepts and approaches and to include con-
finement measures as a particular focus of their risk assessment tasks. 
While the study on which this paper is based was being conducted, EU risk assessors and regula-
tors became active. Working groups have been established and workshops organised in the context 
of the European Food Safety Authority (Schoonejans 2006), the European biotech industry associa-
tion EuropaBio (Barber, personal communication), the European Plant Science Organisation20, and 
the Institute for Prospective Technology Studies of the EU Joint Research Centres. So far, most of 
these activities were designed as expert or technical meetings. Neither environmental/consumer 
NGOs nor food industry representatives participated in these activities. Given the sensitivity of the 
GMO issue in the EU a public debate will inevitably follow. Some of the issues associated with mo-
lecular farming definitely would require such a broad debate, for instance whether at all and under 
what particular conditions commercialisation in food/feed crops and open field cultivation should 
be possible. In that sense the recent hearing at the German Parliament (Deutscher Bundestag 2006) 
where different stakeholder groups and members of parliament could respond to and discuss the 
findings of a technology assessment project on molecular farming (Sauter and Hüsing 2006) can be 
considered a first move towards broadening the debate. 
 
 
20 www.epsoweb.org/Catalog/epso%20workshops/EPSO%20handout%20300106.pdf. 
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Moreover, a broad European debate on risk, benefits and regulatory issues might be complicated by 
conflicting values. Molecular farming is linked or is likely to be linked to the policy arenas of re-
newables, greening of industry or – more generally – to sustainable development on one hand and 
the debate on agricultural problems and reform in the EU on the other hand.  
The former issue often is about substituting traditional chemical production processes by processes 
that are more environmentally sound, e.g. biotechnological processes. In case of PMPs, molecular 
farming is basically substituting one kind of biotechnological process by another. In case of non-
proteinous PMIs, which would be produced on a larger scale as plant-metabolites, a different pic-
ture might emerge. With the help of genetic engineering these substances might be produced more 
efficiently and the properties might be tailored to the application intended. Thus, they might in fact 
serve to render renewables more competitive than before. However, even in this case, the potential 
environmental advantages might conflict with the specific environmental and health risks associated 
with open field production. In that sense molecular farming would find itself located at the cross-
roads of two debates: the risk debate on agricultural biotechnology and the sustainability debate on 
renewables and greening of industry. Some ten years ago a similar but less controversial ‘crossroad’ 
issue, the production of enzymes from genetically modified microorganisms triggered a major con-
flict among the Green Party in Germany (reviewed in Spök et al. 1992) and led to a difficult debate 
about how to value factual environmental benefits vs. hypothetical risks. 
The latter issue is not only of hypothetical nature: in the USA some rural states where cropland is 
abundant and jobs are rare anticipate that pharm crops will generate economic benefits. In the EU, 
which is struggling with heavily subsidised agricultural production, industrial crops are considered 
as an interesting option to diversify European agriculture. In that context pharm crops have been ex-
plicitly welcomed by some commentators (e.g. APA 2005). Individual farmers who – in some Mem-
ber States – are receiving compensations for not cultivating parts of their land are nevertheless com-
ing under pressure and might be tempted to explore other agricultural products, especially if these 
products would promise a higher added value. As this analysis suggests, a higher added value by 
cultivating pharm crops might, however, be restricted to a few contract farmers and relatively small 
areas. GM crops for PMIs that would be grown on a larger scale might in fact provide an interest-
ing alternative though, if the problem of coexistence can be solved. 
In the EU, industrial crops are likely to become a particular focus in the context of the 7th EU frame-
work programme. The recent revival of the biofuel debate is also likely to impact the whole issue 
of industrial crops. Given that food crops such as maize, wheat and rice are envisaged for the pro-
duction of biofuel some of the coexistence and contamination issues might be very similar to those 
discussed for PMIs.  
Beyond these complexities there is another issue that deserves particular attention. Molecular farm-
ing also sits at another crossroads, between “green” (agricultural) biotechnology and “red” biotech-
nology (use of genetic engineering for medical and pharmaceutical purposes). From this setting an 
interesting situation emerges as publics have generally been more supportive of red biotechnology 
than green biotechnology (Gaskell et al. 2001, Nielsen et al. 2002). Thus new lines of reasoning 
and new value conflicts might be expected. There is preliminary evidence from public perception 
studies that consumers would be more supportive for PMP or PMI production compared to first 
generation GM crops (Elbehri 2005, Einsiedel & Medlock 2005, Kirk & McIntosh 2005). No evi-
dence is available from European countries, though. This crossroad situation is also reflected by a 
more complex pattern of policy actors. The biotech (molecular farming) industry might receive sup-
port from certain growers’ and patients’ associations, whereas the environmental and consumer or-
ganisations might be backed up by the food and feed industry. Unprecedented support might meet 
unprecedented opposition. Given the turn towards industrial crops in the EU with the economic po-
tential on one hand and the sensitivity of the GMO issue in the EU on the other, policymakers might 
therefore need to walk another tight rope in order to harness the benefits of this new technology.  
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